Here's Why We're Not Too Worried About Oxford Nanopore Technologies' (LON:ONT) Cash Burn Situation
May 09
Have your own idea? Try our Stock Screener
U.K. (FTSE) Life Sciences Industry Analysis
UpdatedMay 19, 2025
DataAggregated Company Financials
Companies9
- 7D-4.5%
- 3M-10.5%
- 1Y-11.1%
- YTD-12.5%
Over the last 7 days, the Life Sciences industry has dropped 1.4%, driven by declines in Oxford Nanopore Technologies and MaxCyte of 1.3% and 8.3%, respectively. Overall the industry is down 13% in 12 months. Looking forward, earnings are forecast to grow by 30% annually.
Industry Valuation and Performance
Has the U.K. Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Mon, 19 May 2025 | UK£1.7b | UK£313.2m | -UK£193,016,833.70 | 11.5x | -8.6x | 5.3x |
| Wed, 16 Apr 2025 | UK£1.6b | UK£315.1m | -UK£185,785,984.75 | 6.4x | -8.8x | 5.2x |
| Fri, 14 Mar 2025 | UK£1.5b | UK£315.6m | -UK£186,172,571.15 | 6.3x | -7.9x | 4.7x |
| Sun, 09 Feb 2025 | UK£1.9b | UK£307.1m | -UK£195,645,066.48 | 6.8x | -9.8x | 6.2x |
| Tue, 07 Jan 2025 | UK£1.9b | UK£306.7m | -UK£195,372,758.16 | 7.6x | -9.9x | 6.3x |
| Thu, 05 Dec 2024 | UK£2.0b | UK£306.4m | -UK£194,826,079.44 | 8.3x | -10.5x | 6.7x |
| Sat, 02 Nov 2024 | UK£1.9b | UK£304.8m | -UK£192,652,400.50 | 11x | -9.9x | 6.3x |
| Mon, 30 Sep 2024 | UK£2.2b | UK£303.6m | -UK£191,718,111.40 | 11.1x | -11.4x | 7.2x |
| Wed, 28 Aug 2024 | UK£1.8b | UK£295.4m | -UK£188,112,477.00 | 12.4x | -9.8x | 6.3x |
| Fri, 26 Jul 2024 | UK£1.9b | UK£295.4m | -UK£189,849,942.69 | 12.5x | -10x | 6.4x |
| Sun, 23 Jun 2024 | UK£1.5b | UK£296.0m | -UK£190,309,224.21 | 11.5x | -7.7x | 5x |
| Tue, 21 May 2024 | UK£1.6b | UK£294.6m | -UK£187,451,926.31 | 8345.2x | -8.6x | 5.5x |
| Thu, 18 Apr 2024 | UK£1.5b | UK£317.7m | -UK£178,563,563.69 | 11.7x | -8.5x | 4.8x |
| Sat, 16 Mar 2024 | UK£1.9b | UK£295.6m | -UK£212,950,708.15 | 7176.9x | -8.8x | 6.3x |
| Mon, 12 Feb 2024 | UK£2.1b | UK£285.9m | -UK£189,301,187.46 | 7107.4x | -11x | 7.3x |
| Wed, 10 Jan 2024 | UK£3.0b | UK£450.0m | -UK£173,992,809.00 | 63.3x | -17x | 6.6x |
| Fri, 08 Dec 2023 | UK£3.0b | UK£452.9m | -UK£170,728,540.00 | 46.7x | -17.7x | 6.7x |
| Sun, 05 Nov 2023 | UK£3.2b | UK£458.1m | -UK£165,180,912.00 | 47.6x | -19.4x | 7x |
| Tue, 03 Oct 2023 | UK£3.0b | UK£449.0m | -UK£169,366,174.00 | 64.4x | -17.8x | 6.7x |
| Thu, 31 Aug 2023 | UK£3.1b | UK£476.1m | -UK£126,509,605.00 | 70.6x | -24.5x | 6.5x |
| Sat, 29 Jul 2023 | UK£3.4b | UK£476.2m | -UK£124,473,742.00 | 69.6x | -27.3x | 7.1x |
| Mon, 26 Jun 2023 | UK£2.9b | UK£476.6m | -UK£124,746,904.00 | 66.1x | -23.6x | 6.2x |
| Wed, 24 May 2023 | UK£3.2b | UK£477.9m | -UK£122,872,270.00 | 36.7x | -26.2x | 6.7x |
| Fri, 21 Apr 2023 | UK£3.0b | UK£462.7m | -UK£118,273,626.00 | 33.8x | -25.7x | 6.6x |
| Sun, 19 Mar 2023 | UK£2.8b | UK£445.1m | -UK£182,975,029.00 | 39.1x | -15.2x | 6.2x |
| Tue, 14 Feb 2023 | UK£3.2b | UK£443.4m | -UK£182,971,746.00 | 45x | -17.7x | 7.3x |
| Thu, 12 Jan 2023 | UK£3.6b | UK£443.5m | -UK£182,913,837.00 | 47.1x | -19.8x | 8.2x |
| Sat, 10 Dec 2022 | UK£3.4b | UK£446.0m | -UK£179,192,389.00 | 48.8x | -18.7x | 7.5x |
| Mon, 07 Nov 2022 | UK£3.9b | UK£449.0m | -UK£176,445,535.00 | 46.7x | -21.8x | 8.6x |
| Wed, 05 Oct 2022 | UK£3.6b | UK£448.5m | -UK£176,231,475.00 | 42.7x | -20.7x | 8.1x |
| Fri, 02 Sep 2022 | UK£3.7b | UK£370.4m | -UK£190,227,962.00 | 42.8x | -19.2x | 9.9x |
| Sun, 31 Jul 2022 | UK£4.0b | UK£366.4m | -UK£187,984,827.00 | 47.5x | -21.2x | 10.9x |
| Tue, 28 Jun 2022 | UK£3.8b | UK£366.2m | -UK£187,888,828.00 | 40.1x | -20.3x | 10.4x |
| Thu, 26 May 2022 | UK£3.8b | UK£360.2m | -UK£192,140,029.00 | 41x | -19.6x | 10.5x |
Price to Earnings Ratio
-19.6x
Current Industry PE
- Investors are pessimistic on the British Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 8.0x is higher than the industry's current PS ratio of 5.3x.
Past Earnings Growth
- Losses for companies in the Life Sciences industry have remained mostly flat over the last three years.
- Meanwhile revenues for these companies have declined 4.5% per year.
- This means that the cost of doing business could be reducing since sales have declined but losses haven't fallen much further.
Industry Trends
Which industries have driven the changes within the U.K. Healthcare industry?
| GB Market | 0.90% | |
| Healthcare | 0.41% | |
| Life Sciences | -4.47% | |
| Clinical Research and Equipment | -4.47% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| DXRX Diaceutics | UK£1.32 | 5.6% +UK£5.9m | 11.4% | PS4.3x | |
| HVO hVIVO | UK£0.18 | 4.3% +UK£5.1m | -32.3% | PE11.5x | |
| PRM Proteome Sciences | UK£0.04 | 29.4% +UK£2.7m | 14.3% | PS2.4x | |
| FAB Fusion Antibodies | UK£0.068 | 10.7% +UK£736.6k | 95.7% | PS4.2x | |
| PYC Physiomics | UK£0.0042 | 1.2% +UK£15.2k | -66.4% | PS2.3x |